Browsing tag:

colorectal cancer


On August 3, 2012, the United States Food and Drug Administration (USFDA) approved ziv-aflibercept injection ( Zaltrap, made by Sanofi and Regeneron Pharmaceuticals, Inc.) for use in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) for the treatment of patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following treatment with an[…]

Read More

Regarded as a blockbuster drug used to treat both metastatic breast and colorectal cancer, Capecitabine is also known by the trade name Xeloda, which is marketed by Roche Pharamaceuticals. Capecitabine, CAS# 154361-50-9, is waiting in the wings to become a generic boon in the pharmaceutical industry, as the patent for Xeloda meets an expiration in[…]

Read More

Clinical development of an exciting new recombinant fusion protein, Aflibercept, is underway. As an inhibitor of VEGF, or the vascular endothelial growth factor receptor, aflibercept is currently in a phase III trial for second line metastatic colorectal cancer. This trial for Aflibercept is being conducted by Sanofi-Aventis and Regeneron Pharmaceuticals. Additional trials currently in progress[…]

Read More

This website uses cookies. By using our site, you agree to our terms of service